Indo Us Biotech balance sheet

As of Sep 2026

Total assets: ₹140cr+19.7% on Sep 2025
Shareholders' equity: ₹91.9cr+6.0% on Sep 2025
Total debt: ₹44.2cr+59.8% on Sep 2025
Cash and investments: ₹2.3cr+292.5% on Sep 2025

₹ crore except per share

Tap a line for its trend	H1 FY27Sep 2026	FY26Mar 2026	FY25Mar 2025

Non-current assets
	11.2	11.2	10.2
	1.0	0.5	—
	0.3	0.2	0.0
	0.3	0.2	0.0
	0.5	0.5	0.7
	0.0	0.0	0.2
	13.0	12.4	11.1
Current assets
	86.0	100.0	70.7
	36.3	13.8	15.0
	2.3	6.1	0.2
	2.6	0.8	0.8
	41.2	20.7	16.0
	0.1	0.1	0.0
	127	121	86.7
	140	133	97.8
Equity
	20.1	20.1	20.1
	71.8	72.5	58.5
	91.9	92.5	78.5
	91.9	92.5	78.5
Liabilities
	8.5	1.0	2.9
	8.5	1.0	2.9
	0.1	0.1	0.1
	8.5	1.0	3.0
	35.7	36.1	11.9
	2.0	0.4	1.2
	2.1	—	—
	39.8	36.5	13.1
	0.0	0.0	0.0
	0.0	0.4	0.3
	2.5	2.5	3.0
	39.9	39.5	16.3
	48.4	40.6	19.3
	140	133	97.8
Trade payables — MSME split
	0.0	0.0	0.2
	2.0	0.4	1.0

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

INDOUS₹78.36

Indo Us Biotech Limited

· FMCG & Retail

₹ CrorePeersKOHINOOR NATHBIOGEN AGRITECH SARVESHWAR SUKHJITS REGAAL BSHSL GULPOLYMcap ₹157 Cr

View

In ₹ Crore except Per Share As of	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Non-current Assets
+ Property, Plant & Equipment	10.2	11.2	11.2
+ Capital Work-in-Progress	—	0.5	1.0
+ Long-term Loans	0.0	0.2	0.3
Non-current Financial Assets	0.0	0.2	0.3
+ Deferred Tax Assets	0.7	0.5	0.5
+ Other Non-current Assets	0.2	0.0	0.0
Total Non-current Assets	11.1	12.4	13.0
Current Assets
+ Inventories	70.7	100.0	86.0
+ Trade Receivables	15.0	13.8	36.3
+ Cash & Cash Equivalents	0.2	6.1	2.3
+ Other Current Financial Assets	0.8	0.8	2.6
Current Financial Assets	16.0	20.7	41.2
+ Other Current Assets	0.0	0.1	0.1
Total Current Assets	86.7	120.7	127.3
Total Assets	97.8	133.1	140.3
Equity
+ Equity Share Capital	20.1	20.1	20.1
+ Other Equity / Reserves	58.5	72.5	71.8
Equity — Owners of Parent	78.5	92.5	91.9
Total Equity	78.5	92.5	91.9
Liabilities
+ Borrowings — Non-current	2.9	1.0	8.5
Non-current Financial Liabilities	2.9	1.0	8.5
+ Provisions — Non-current	0.1	0.1	0.1
Non-current Liabilities	3.0	1.0	8.5
+ Borrowings — Current	11.9	36.1	35.7
+ Trade Payables	1.2	0.4	2.0
+ Other Current Financial Liab	—	—	2.1
Current Financial Liabilities	13.1	36.5	39.8
+ Provisions — Current	0.0	0.0	0.0
+ Current Tax Liabilities	0.3	0.4	0.0
+ Other Current Liabilities	3.0	2.5	2.5
Current Liabilities	16.3	39.5	39.9
Total Liabilities	19.3	40.6	48.4
Total Equity & Liabilities	97.8	133.1	140.3
Trade Payables — MSME split
+ Dues to Micro & Small — Current	0.2	0.0	0.0
+ Dues to Other Creditors — Current	1.0	0.4	2.0

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.